Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1 091,51
-2,30
-0,21%
—1 093,811 096,521 100,221 091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1 237,98
-16,83
-1,34%
—1 254,811 253,011 253,871 226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1 744,71
-16,40
-0,93%
—1 761,111 764,271 766,881 744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3 260,69
+48,86
+1,52%
—3 211,833 227,213 268,383 226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1 466,80
-7,72
-0,52%
—1 474,521 479,031 481,041 466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2 397,50
+5,38
+0,22%
—2 392,122 396,952 421,222 382,32——
Q1 2026 earnings • released • EPS beat +8,04% • Revenue beat +0,55%
See results
AMG:ETR
Amgen Inc
296,80 €
+2,65%
(+7,65) 1D
30 ապր, 17:35:37 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for AMG...
Open
287,50 €
High
296,80 €
Low
286,90 €
Mkt. cap
178,00 մլրդ
Avg. vol.
309,00
Volume
346,00
52-wk high
333,00 €
52-wk low
230,00 €
No. of employees
32 հզր
News stories
From sources across the web
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000. Wikipedia
About Amgen Inc
CEORobert A. Bradway
Employees31,5 հզր
Founded08 ապր, 1980 թ.
HeadquartersԹաուզենդ Օուքս, Կալիֆոռնիա, Միացյալ Նահանգներ
Sector-
Websiteamgen.com
Last report
30 ապր, 2026 թ.
Fiscal Period
Q1 2026
Normalized EPS / Estimate
5,15/ (4,77 est.)USD
+8,04%beat
Revenue / Estimate
8,62 մլրդ/ (8,57 մլրդ est.)USD
+0,55%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025 թ. մրտ
2025 թ. հնս
2025 թ. սեպ
2025 թ. դեկ
Revenue
8,15 մլրդ
9,18 մլրդ
9,56 մլրդ
9,87 մլրդ
Cost of goods sold
2,60 մլրդ
2,67 մլրդ
2,74 մլրդ
2,68 մլրդ
Cost of revenue
2,60 մլրդ
2,67 մլրդ
2,74 մլրդ
2,68 մլրդ
Research and development expenses
1,49 մլրդ
1,74 մլրդ
1,90 մլրդ
2,14 մլրդ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,69 մլրդ
1,69 մլրդ
1,72 մլրդ
1,95 մլրդ
Operating expense
3,20 մլրդ
3,50 մլրդ
3,55 մլրդ
4,18 մլրդ
Total operating expenses
5,81 մլրդ
6,18 մլրդ
6,29 մլրդ
6,85 մլրդ
Operating income
2,34 մլրդ
3,00 մլրդ
3,26 մլրդ
3,01 մլրդ
Other non operating income
-36,00 մլն
-113,00 մլն
181,00 մլն
143,00 մլն
EBT including unusual items
1,97 մլրդ
1,57 մլրդ
3,92 մլրդ
1,51 մլրդ
EBT excluding unusual items
1,66 մլրդ
2,37 մլրդ
2,72 մլրդ
2,51 մլրդ
Income tax expense
243,00 մլն
136,00 մլն
705,00 մլն
181,00 մլն
Effective tax rate
12,32%
8,67%
17,98%
11,96%
Other operating expenses
30,00 մլն
68,00 մլն
-71,00 մլն
82,00 մլն
Net income
1,73 մլրդ
1,43 մլրդ
3,22 մլրդ
1,33 մլրդ
Net profit margin
21,23%
15,60%
33,65%
13,51%
Earnings per share
4,90
6,02
5,64
5,29
Interest and investment income
-
-
-
408,00 մլն
Interest expense
-723,00 մլն
-694,00 մլն
-685,00 մլն
-1,06 մլրդ
Net interest expenses
-723,00 մլն
-694,00 մլն
-685,00 մլն
-653,00 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
3,73 մլրդ
4,34 մլրդ
4,57 մլրդ
4,02 մլրդ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer